Results 241 to 250 of about 136,094 (289)

Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. [PDF]

, 2008
Jimenez, Sergio A., Rosenbloom, Joel
core   +1 more source

Targeting the ARRDC3–DRP1 Axis via hUMSC‐Derived Exosomal CRYAB for Neuroprotection in Cerebral Ischemia/Reperfusion Injury

Advanced Healthcare Materials, EarlyView.
Intranasally administered hUMSC‐derived exosomes modulate the CRYAB–ARRDC3–Drp1 axis, alleviating mitochondrial dysfunction and ferroptosis, enhancing neuronal survival, reducing oxidative stress, and promoting functional recovery in ischemia‐reperfusion injury, offering a promising therapeutic strategy for ischemic stroke.
Rong ji, Zengyu Zhang, Zhuohang Liu, Kaicheng Yang, Xueyu Mao, Min Chu, Yong Wang, Jing Zhao   +7 more
wiley   +1 more source

Boron‐Doped Nano‐Crystalline Coated Carbon Fibers for Phasic Dopamine Sensing

Advanced Healthcare Materials, EarlyView.
This uniform coating presents a mix of graphitic and diamond‐like carbon to create a mechanically and electrically robust alternative for the electrochemical detection of dopamine. The electrodes in this work possess the equivalent sensitivity to the state‐of‐the‐art FSCV dopamine detecting electrodes, whilst demonstrating an ability to withstand ...
Simon J. Higham, Juan M. Rojas Cabrera, Youngjong Kwak, Lydia Hong, Andre Chambers, Athavan Nadarajah, Sorel E. De Leon, Young Jun Jung, Negin Jalilinejad, Charles Blaha, Dong Pyo Jang, Yoonbae Oh, Kendall Lee, Alastair Stacey, Shaun L. Cloherty, Michael R. Ibbotson, David J. Garrett, Steven Prawer, Hojin Shin, Wei Tong   +19 more
wiley   +1 more source

Mixed connective tissue disease

, 2012
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mixed connective tissue disease

Clinics in Dermatology, 1985
Abstract Mixed connective tissue disease (MCTD) was first described by Gordon Sharp, 1 in 1972, as a distinct connective tissue disorder characterized by overlapping features of systemic lupus erythematosus (SLE), progressive systemic sclerosis (PSS), and dermato/polymyositis (DP/PM).
D T, Schreiner, J L, Jorizzo
openaire   +3 more sources

Mixed Connective Tissue Disease

Current Opinion in Rheumatology, 2000
A defining feature of mixed connective tissue disease (MCTD) is the presence of antibodies against the U1-ribonucleoprotein (RNP) complex, but other autoantibodies in MCTD have recently been described. Research has also further elucidated the immune responses directed against U1-RNP in humans and in murine models of disease.
R W, Hoffman, E L, Greidinger
openaire   +2 more sources

Mixed Connective-Tissue Disease

New England Journal of Medicine, 1977
Coping with chronic illness has become a personal experience for me. For the past 13 years, I have gone through various stages of coping with mixed connective tissue disease (MCTD), a rare collagen-vascular disease of unknown origin that resembles scleroderma, lupus erythematosus, and polymyositis.
openaire   +4 more sources

Mixed connective tissue disease

Best Practice & Research Clinical Rheumatology, 2016
The concept of mixed connective tissue disease (MCTD) as a separate connective tissue disease (CTD) has persisted for more than four decades. High titers of antibodies targeting the U1 small nuclear ribonucleoprotein particle (U1 snRNP) in peripheral blood are a sine qua non for the diagnosis of MCTD, in addition to distinct clinical features including
Ragnar, Gunnarsson, Siri Opsahl, Hetlevik, Vibke, Lilleby, Øyvind, Molberg   +3 more
openaire   +2 more sources